Schizophrenia: How should we look at it?

[1] ASTONJONES G, 1991, J NEUROSCI, V11, P760

[2] BENES FM, 1995, ARCH GEN PSYCHIAT, V52, P1015

[3] CHIODO LA, 1983, J NEUROSCI, V3, P1607

[4] Deutch A. Y, 1992, J NEURAL TRANSM-SUPP, P61

[5] DEWEY SL, 1995, J NEUROSCI, V15, P821

[6] ERESHEFSKY L, 1993, CAN J PSYCHIAT, V38, pS80

[7] TREATMENT STRATEGIES FOR SCHIZOPHRENIA [J]. PSYCHIATRIC ANNALS, 1995, 25 (05) : 285 - 296

[8] ERESHEFSKY L, 1989, CLIN PHARMACY, V8, P691

[9] ANTIPSYCHOTIC-DRUGS BLOCK PHENCYCLIDINE RECEPTOR-MEDIATED NEUROTOXICITY [J]. BIOLOGICAL PSYCHIATRY, 1993, 34 (1-2) : 119 - 121

[10] GRACE AA, 1992, J NEURAL TRANSM-SUPP, V36, P91

[1] ASTONJONES G, 1991, J NEUROSCI, V11, P760

[2] BENES FM, 1995, ARCH GEN PSYCHIAT, V52, P1015

[3] CHIODO LA, 1983, J NEUROSCI, V3, P1607

[4] Deutch A. Y, 1992, J NEURAL TRANSM-SUPP, P61

[5] DEWEY SL, 1995, J NEUROSCI, V15, P821

[6] ERESHEFSKY L, 1993, CAN J PSYCHIAT, V38, pS80

[7] TREATMENT STRATEGIES FOR SCHIZOPHRENIA [J]. PSYCHIATRIC ANNALS, 1995, 25 (05) : 285 - 296

[8] ERESHEFSKY L, 1989, CLIN PHARMACY, V8, P691

[9] ANTIPSYCHOTIC-DRUGS BLOCK PHENCYCLIDINE RECEPTOR-MEDIATED NEUROTOXICITY [J]. BIOLOGICAL PSYCHIATRY, 1993, 34 (1-2) : 119 - 121

[10] GRACE AA, 1992, J NEURAL TRANSM-SUPP, V36, P91